Upvote
Downvote
Associate Director, Formulation Development
Share Job
- Suggest Revision
$200,000 - $210,000 a year
Full-time
- Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration for both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant is currently conducting BEACON-IPF, a Phase 2b/3 trial of bexotegrast for the treatment of IPF and INTEGRIS-PSC, a Phase 2a trial of bexotegrast for the treatment of PSC.
- The Associate Director, Formulation Development will conduct/lead pre-formulation, formulation development, tech transfer, scale-up, and manufacturing activities at Pliant and it's CMO partners.
- This role provides scientific expertise in solid oral dosage formulation development, late-stage process development, oversight of GMP drug product manufacturing at contract development sites, authoring global regulatory filings (INDs, IMPDs, etc.)
- and technical oversight of preclinical formulation development.
- Reporting to Senior Director, Formulation Development, this position will collaborate with cross functional departments and other CMC functions in a fast-paced high growth environment team to ensure progression of Pliant small molecules from discovery through development/commercialization.
Active Job
Updated TodaySimilar Job
Relevance
Active